NanoBio Corporation Enters into Two Phase III Trials for their Novel Topical Treatment for Cold Sores

May 16, 2011

NanoBio has licensing agreement with GlaxoSmithKline for this technology

The cold sore treatment, known as NB-001, will be evaluated in multicenter trials with 1,700 subjects. The trials are expected to end in 2012. GSK Switzerland first received exclusive rights to NB-001 in the US and Europe for over-the-counter treatment of cold sores back in 2009. GSK currently has the OTC cold sore treatment Abreva. NanoBio Corporation is a privately-held biopharmaceutical company that develops and commercializes innovative therapeutics and treatments using its proprietary nanoemulsion-based platform technology.

↑ Back to Nano World News™